Bloomberg the Company

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Follow Us

Industry Products

Markets & Finance

Robbie Stephens Downgrades Guidant


Robertson Stephens downgraded Guidant Corp. (GDT) to market perform from buy and cut its estimates for the medical-device maker.

On Tuesday an FDA panel said they would not recommend the approval of Guidant's Contak CD/Easytrak system. Analyst Wade King says it's highly unlikely the FDA will move against a panel recommendation. He says the same panel voted Tuesday to recommend Medtronic's InSyc device. Without domestic competition, King thinks rival Medtronic could have an early foothold in the U.S. congestive heart failure (CHF) market.

King cut Guidant's $1.63 2001 EPS estimate to $1.60, and cut the $1.95 2002 EPS estimate to $1.88 because of the panel's results and the company's likely need to pursue further tests for U.S. approval. Guidant still has long-term value, but King notes that near-term catalysts are limited. He has a $34 target.


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus